Nevertheless, the response rate to these therapies in CRC remains modest.[64] In our investigations, we observed that the targeted deletion of VTN in CAF markedly potentiated the therapeutic efficacy of PD‐1 inhibition in mouse models of both subcutaneous and AOM/DSS‐induced tumors. The gene discussed is PDCD1; the disease is infectious otitis media.